Halozyme Announces Actions To Focus Strategy On ENHANZE(R) Drug Delivery Technology

Initiates Organizational Restructuring to Close Oncology Operations, Reducing Headcount by Approximately 55%Board Authorizes Initiation of Capital Return with Share Repurchase Program for $350 Million Over Three YearsFirst Quarter of Sustainable Pr...Biopharmaceuticals, Drug Delivery
Halozyme Therapeutics, ENHANZE